BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36088195)

  • 1. Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.
    Ye JJ; Ren SQ; Bao YG
    Asian J Surg; 2023 Feb; 46(2):1163-1164. PubMed ID: 36088195
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    Pfister C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulié M; Allory Y; Harter V; Culine S;
    J Clin Oncol; 2022 Jun; 40(18):2013-2022. PubMed ID: 35254888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
    Culine S; Harter V; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Abadie-Lacourtoisie S; Geoffrois L; Fiore FD; Roubaud G; Barthélémy P; Voog E; Emambux S; Serrate C; Saldana C; Nguyen-Tan-Hon T; Loriot Y; Eymard JC; Huillard O; Rolland F; Houédé N; Spano JP; Demery ME; Vieillot S; L'Haridon T; Hilgers W; Allory Y; Pfister C;
    Clin Genitourin Cancer; 2021 Dec; 19(6):554-562. PubMed ID: 34602349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
    Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
    Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
    Montazeri K; Dranitsaris G; Thomas JD; Curran C; Preston MA; Steele GS; Kilbridge KL; Mantia C; Ravi P; McGregor BA; Mossanen M; Sonpavde G
    Urol Oncol; 2021 Dec; 39(12):834.e1-834.e7. PubMed ID: 34162500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
    Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
    Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
    Joyce DD; Wymer KM; Sharma V; Moriarty JP; Borah BJ; Geynisman DM; Plimack ER; Costello BA; Pagliaro LC; Boorjian SA
    Cancer; 2022 Dec; 128(24):4194-4202. PubMed ID: 36251574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
    Riaz IB; Hussain SA
    Eur Urol; 2021 Feb; 79(2):222-224. PubMed ID: 33012577
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
    Kaneko G; Kikuchi E; Matsumoto K; Obata J; Nakamura S; Miyajima A; Oya M
    Jpn J Clin Oncol; 2011 Jul; 41(7):908-14. PubMed ID: 21665907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
    Pfister C; Harter V; Allory Y; Radvanyi F; Culine S;
    Contemp Clin Trials Commun; 2020 Mar; 17():100536. PubMed ID: 32083220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
    Culine S; Harter V; Krucker C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Fontugne J; Allory Y; Pfister C;
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic urothelial cancer in the post-MVAC era.
    Cohen EE; Stadler WM
    World J Urol; 2001 Apr; 19(2):126-32. PubMed ID: 11374315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
    Cohen MH; Rothmann M
    J Clin Oncol; 2001 Feb; 19(4):1229-31. PubMed ID: 11181690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.